Built on one of the world's largest Parkinson's and dementia datasets and adopted across major U.S. health systems and NHS Trusts, Kneu is creating a population-scale foundation for managing neurodegenerative decline

Kneu's smartphone platform, FDA-cleared for Parkinson's tremor measurement, is the first clinically validated system to track motor, speech and cognitive change entirely by phone, embedding proactive monitoring into daily life and clinical workflows

Powered by clinically trained AI models that turn voice, movement and memory into predictive biomarkers, Kneu helps detect neurological decline earlier and support timely intervention

LONDON, Oct. 9, 2025 /PRNewswire/ -- Kneu Health, a precision neurology platform for Parkinson's and dementia, today announced the close of a $5.6 million oversubscribed seed round. Co-led by Oxford Science Enterprises and Cedars-Sinai, with participation from Social Impact Enterprises, JIMCO, G.K. Goh Ventures and SXSW London, the funding will accelerate U.S. expansion by scaling Parkinson's deployments, expanding commercial capacity, and publishing outcomes data, while also advancing dementia monitoring. The round brings Kneu's total funding to date to $11.2 million.

Neurological disorders are surging into a major public health crisis. Parkinson's is the fastest-growing neurological disease worldwide, while dementia cases are projected to triple by 2050. In the U.S., patients often wait many months between specialist visits, and neurologist shortages are leaving health systems unable to keep up with demand. The result is a care model that reacts too late, after decline has already accelerated, instead of providing the continuous support patients and families need.

Kneu's technology builds on more than a decade of longitudinal research, expanded with over 500,000 digital measures from 1,400+ users across NHS and U.S. deployments. Clinically trained AI models analyze speech, movement and cognition to generate predictive biomarkers that stratify risk across populations and guide targeted interventions. FDA clearance for smartphone-based Parkinson's tremor measurement affirms the platform's clinical rigor and enables proactive monitoring to be embedded directly into daily life and care pathways. Clinicians report delivering better patient care, with 67% of cases achieving faster-than-standard access to treatment and data-driven insights supporting medication changes for over half of patients. Patients themselves report up to a 30% improvement in knowledge, confidence, and self-management—translating into greater independence and daily functioning. NHS pilots demonstrate the platform's ability to boost efficiency by 30%, reduce emergency admissions, and shift Parkinson's care from reactive to planned settings—equivalent to saving 1,000 bed days in a single provider.

"We've spent the last two years proving that remote monitoring can transform neurological care. Clinicians are getting clearer insight without added workload, patients no longer face months of uncertainty between visits, and gain confidence that changes will be recognized rather than missed," said Caroline Cake, co-founder and CEO, Kneu Health. "This funding allows us to bring that model to the U.S. at the right moment, when health systems are ready to move beyond band-aid solutions and embrace continuous neurological care as core infrastructure, accessible to anyone with a smartphone."

With first contracts underway at Cedars-Sinai and Mass General Brigham and participation in the Global Incubator Programme at Texas Medical Center Innovation (TMCi), Kneu has established a presence in America's most influential medical ecosystems. Together, these efforts point to a larger shift: neurology can no longer rely on episodic care alone, and Kneu is showing that continuous data belongs at the center of how health systems operate.

"Neurology has had plenty of algorithms. What it has lacked is longitudinal signal that clinicians can trust and act on inside real workflows. Kneu has turned everyday phone interactions into a clinically governed measurement layer that scales across populations without new hardware or staffing," said Joel Schoppig, Health Tech Investment Principal, Oxford Science Enterprises. "With evidence emerging on both sides of the Atlantic, Kneu is laying the foundation for a reference dataset and operating platform in Parkinson's and dementia that raises standards of care while finally making the economics work for hospitals and payers."

"The strength of Kneu's approach is how rigorous science is carried through into day-to-day practice. By giving neurologists longitudinal signal between visits, the platform reduces avoidable appointments and sharpens focus on the cases that matter most," said Nirdesh Gupta, Managing Director, Cedars-Sinai Technology Ventures. "This is the kind of clinically governed infrastructure we look for, and it is why we chose to back Kneu and bring it into our ecosystem."

About Kneu Health 

Kneu Health is pioneering continuous intelligence for neurological care through smartphone-based monitoring of Parkinson's and dementia. Built on Oxford University's decade-long longitudinal research and validated across leading health systems, the company's FDA-cleared platform transforms daily interactions into clinical insights that enable earlier intervention and personalized care. Backed by Oxford Science Enterprises, Cedars-Sinai, and a global syndicate of investors, Kneu operates across eight NHS Trusts and flagship U.S. health systems. Learn more at kneuhealth.com.

Media contact:

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/kneu-health-secures-5-6m-to-scale-next-generation-neurology-care-302579142.html

SOURCE Kneu Health